Scholarlink

Introduction <p>Aldosterone synthase inhibitors are a class of medication that target aldosterone biosynthensis while addressing the current limitations of conventional renin-angiotensin-aldosterone inhibitors. This review aims to explore the emerging role of lorundrostat and baxdrostat, efficacy and safety in the management of treatment-resistant and poorly controlled hypertension.</p> Results <p>A narrative review was conducted, including six (6) clinical trials published between 2016 and 2025. Lorundrostat and baxdrostat demonstrated dose-dependent reductions in blood pressure across evaluated trials. In lorundrostat studies, plasma renin activity increased in association with aldosterone suppression, and an overall favorable safety profile was reported. Baxdrostat demonstrated selective inhibition of aldosterone synthase in early-phase studies, and studies reported mild hyperkalemia and decreased renal function at higher doses. Lorundrostat was found to have comparable efficacy in patients with and without suppressed plasma renin activity, based on subgroup analyses within individual trials.</p> Conclusion <p>Direct head-to-head comparative data between lorundrostat and baxdrostat are not currently available, and differences in selectivity or off-target effects are derived from separate clinical investigations. While current data support their efficacy and safety in early clinical trials, further large-scale studies are needed to establish their long-term outcomes, cost-effectiveness, and integration into clinical practice guidelines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aldosterone Synthase Inhibitors: a Review of Lorundrostat and Baxdrostat in Treatment-Resistant Hypertension

  • 期刊论文

  • 发表日期：

    2026年4月25日

查看全文
  • Ikponmwosa Jude Ogieuhi,
  • Chidera Stanley Anthony,
  • Victor Oluwatomiwa Ajekiigbe,
  • Kelvin Obinna Omeje,
  • Boluwaduro Abasiekem Adeyemi,
  • Oluwamisimi Mary Abib,
  • Efosa Peace Iyawe,
  • Chukwuagoziem Onuigbo,
  • Christopher Abiodun Adegbesan,
  • Charity Onetemizeh Ayoson,
  • Kayode Ogunniyi,
  • Andrew Ndakotsu

摘要

Introduction

Aldosterone synthase inhibitors are a class of medication that target aldosterone biosynthensis while addressing the current limitations of conventional renin-angiotensin-aldosterone inhibitors. This review aims to explore the emerging role of lorundrostat and baxdrostat, efficacy and safety in the management of treatment-resistant and poorly controlled hypertension.

Results

A narrative review was conducted, including six (6) clinical trials published between 2016 and 2025. Lorundrostat and baxdrostat demonstrated dose-dependent reductions in blood pressure across evaluated trials. In lorundrostat studies, plasma renin activity increased in association with aldosterone suppression, and an overall favorable safety profile was reported. Baxdrostat demonstrated selective inhibition of aldosterone synthase in early-phase studies, and studies reported mild hyperkalemia and decreased renal function at higher doses. Lorundrostat was found to have comparable efficacy in patients with and without suppressed plasma renin activity, based on subgroup analyses within individual trials.

Conclusion

Direct head-to-head comparative data between lorundrostat and baxdrostat are not currently available, and differences in selectivity or off-target effects are derived from separate clinical investigations. While current data support their efficacy and safety in early clinical trials, further large-scale studies are needed to establish their long-term outcomes, cost-effectiveness, and integration into clinical practice guidelines.